Notably, the nanocarrier system targeting FABP5 elevates PD‐L1 expression, and the combination of RFA with anti‐PD‐L1 therapy demonstrates synergistic efficacy against HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.